Trustmark National Bank Trust Department Biogen Inc. Transaction History

Trustmark National Bank Trust Department

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $40,226 - $45,117	-185 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $1.31 Million - $1.45 Million	-5,988 Reduced 97.0%	185 $43,000
Q1 2019 May 13, 2019	SELL	$216.71 - $338.96 $7,584 - $11,863	-35 Reduced 0.56%	6,173 $1.46 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $3,620 - $4,585	13 Added 0.21%	6,208 $1.87 Million
Q3 2018 Feb 22, 2019	SELL	$293.51 - $383.83 $235,982 - $308,599	-804 Reduced 11.49%	6,195 $2.19 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $213,968 - $279,812	729 Added 11.63%	6,999 $2.47 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $5,150 - $6,138	20 Added 0.32%	6,270 $1.82 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $1.63 Million - $2.3 Million	6,250 New	6,250 $1.71 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Trustmark National Bank Trust Department, based on Form 13F filings with the SEC.

Stay updated on Trustmark National Bank Trust Department with notifications on news.